{"id":553544,"date":"2026-07-17T00:00:09","date_gmt":"2026-07-17T00:00:09","guid":{"rendered":"https:\/\/www.newsbeep.com\/ie\/553544\/"},"modified":"2026-07-17T00:00:09","modified_gmt":"2026-07-17T00:00:09","slug":"cutting-edge-drug-shows-promise-for-patients-with-nras-driven-melanoma","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/ie\/553544\/","title":{"rendered":"Cutting-Edge Drug Shows Promise for Patients with NRAS-Driven Melanoma"},"content":{"rendered":"

Newswise \u2014 A research team from\u00a0Huntsman Cancer Institute<\/a>\u00a0at the\u00a0University of Utah (the U)<\/a>\u00a0reports\u00a0that a groundbreaking\u00a0pathway-targeted therapy could be an effective treatment for certain melanoma patients and fill an\u00a0unmet\u00a0clinical need\u00a0for patients with advanced disease.\u00a0\u00a0
\u00a0
Martin McMahon, PhD<\/a>, senior director of preclinical translation at Huntsman Cancer Institute and professor of dermatology at the U, evaluated an investigative compound of the drug daraxonrasib in\u00a0NRAS-driven\u00a0melanoma<\/a>.\u00a0NRAS-driven melanoma is an aggressive type of skin cancer\u00a0driven\u00a0by\u00a0mutations\u00a0in the\u00a0NRAS\u00a0gene.\u00a0Daraxonrasib, developed by\u00a0Revolution Medicines<\/a>,\u00a0targets and inhibits\u00a0RAS, a\u00a0protein\u00a0that drives\u00a0cancer when altered.\u00a0NRAS\u00a0is a subtype of\u00a0RAS\u00a0that\u00a0is\u00a0mutated\u00a0in\u00a0roughly a\u00a0quarter of melanoma\u00a0cases.\u00a0\u00a0\u00a0
\u00a0
The results of\u00a0daraxonrasib\u00a0as a treatment for metastatic pancreatic cancer\u2014in which it doubled\u00a0patients\u2019\u00a0life expectancy\u00a0in a Phase 3 clinical trial\u2014recently\u00a0received a\u00a0standing\u00a0ovation from thousands of physicians<\/a>\u00a0at the\u00a0American Society of Clinical Oncology Annual Meeting<\/a>.\u00a0Huntsman Cancer Institute\u00a0was one of just 60\u00a0hospitals\u00a0worldwide who offered\u00a0that\u00a0trial\u00a0(RASolute\u00a0302<\/a>).\u00a0\u00a0\u00a0
\u00a0
\u201cThe\u00a0remarkable\u00a0success of\u00a0daraxonrasib\u00a0in the treatment of pancreatic cancer indicates that we are\u00a0in an\u00a0era where even the most recalcitrant\u00a0RAS-driven cancers can be treated,\u201d says McMahon. \u201cOur data strongly supports the potential future clinical utility of treating patients with\u00a0NRAS-driven melanoma with\u00a0daraxonrasib.\u201d\u00a0
\u00a0
McMahon and his team evaluated the effectiveness of the\u00a0RAS\u00a0inhibitor in numerous preclinical models, including melanoma samples from patients. The\u00a0results of the study<\/a>\u00a0have been published in\u00a0Cancer Research<\/a>, a journal of the\u00a0American Association for Cancer Research<\/a>.\u00a0\u00a0
\u00a0
\u201cAll our\u00a0NRAS-driven models were very responsive to this\u00a0RAS\u00a0inhibitor. It\u2019s\u00a0actually quite\u00a0rare that we see shrinkage of\u00a0NRAS-driven tumors,\u201d says\u00a0Mona Foth, PhD<\/a>, research scientist at Huntsman Cancer Institute and first author of the publication. \u201cIt\u2019s inspiring to think that these results could potentially lead to a new patient therapy that will help them overcome their disease.\u201d\u00a0\u00a0<\/p>\n

Melanoma is the deadliest form of skin cancer, and their research aims to help fulfill an\u00a0unmet clinical need in patients with metastatic\u00a0disease. These patients usually receive\u00a0immunotherapy<\/a>, the harnessing of a patient\u2019s own immune system, as the earliest form of\u00a0treatment. Immunotherapy\u00a0has revolutionized metastatic melanoma care.\u00a0Foth says the treatment is effective in about half of melanoma patients, sometimes with deep and durable responses.\u00a0\u00a0\u00a0
\u00a0
If immunotherapy fails or becomes less effective, physicians switch to targeted therapies as a secondary line of treatment. Targeted therapies\u00a0attack\u00a0oncoproteins and their effectors\u00a0to\u00a0kill cancer cells or\u00a0slow\u00a0their\u00a0growth.\u00a0
\u00a0
\u201cPatients with other mutations like\u00a0BRAF\u00a0have access to clinically approved secondary\u00a0lines of treatment.\u00a0But\u00a0patients with\u00a0NRAS-driven melanoma do not have effective\u00a0targeted therapies to treat their cancer,\u201d says McMahon. \u201cDaraxonrasib\u00a0is a targeted therapy that may provide another path for treatment and hope for patients affected by this devastating disease.\u201d\u00a0
\u00a0
The team also\u00a0observed\u00a0that some of the models became resistant to the drug, as often\u00a0happens in patients taking\u00a0pathway-targeted therapies. Resistance to\u00a0daraxonrasib\u00a0was\u00a0tied to mutations in the mitogen-activated protein kinase (MEK1),\u00a0a protein downstream of RAS,\u00a0or to loss of expression of cyclophilin A,\u00a0a\u00a0chaperone protein\u00a0required\u00a0for the\u00a0inhibitory action\u00a0of\u00a0daraxonrasib\u00a0toward RAS proteins.\u00a0\u00a0\u00a0
\u00a0
\u201cWe will need to do more research\u00a0to\u00a0find\u00a0drug combinations, based\u00a0on a backbone of\u00a0daraxonrasib, that will increase the depth and durability of melanoma patient responses,\u201d says McMahon.\u00a0
\u00a0
McMahon\u00a0and Foth\u00a0hope the drug will move into a clinical trial for patients who are either ineligible for immunotherapy or\u00a0whose immunotherapy did not work.\u00a0\u00a0
\u00a0
“This\u00a0research reflects the power of Huntsman Cancer Institute’s integrated approach, where laboratory discovery, translational research, and clinical trials come together to accelerate progress for patients,\u201d\u00a0says\u00a0Neli Ulrich, PhD, MS<\/a>,\u00a0executive director of the Comprehensive Cancer Center and\u00a0chief scientific\u00a0officer\u00a0at Huntsman Cancer Institute, Jon and Karen Huntsman Presidential Professor in Cancer\u00a0Research, and professor of population health sciences at the U.\u00a0\u201cWe are proud to contribute to advances that have the potential to change treatment options for our patients with melanoma. This is of utmost importance\u00a0in Utah and the Mountain West, where melanoma is\u00a0a very common\u00a0cancer.\u201d\u00a0\u00a0
\u00a0
The critical research happening every day at Huntsman Cancer Institute is supported by the National Institutes of Health\/National Cancer Institute, including Cancer Center Support Grant P30 CA042014, as well as Huntsman Cancer Foundation.\u00a0<\/p>\n

About Huntsman Cancer Institute at the University of Utah
Huntsman Cancer Institute<\/a>\u00a0at the\u202fUniversity of Utah\u00a0(the U) is the National Cancer Institute-designated Comprehensive Cancer Center for Utah, Idaho, Montana, Nevada, and Wyoming. With a legacy of innovative cancer research, groundbreaking discoveries, and world-class patient care, we are transforming the way cancer is understood, prevented, diagnosed, treated, and survived. Huntsman Cancer Institute focuses on delivering a cancer-free frontier to all communities in\u00a0the area we serve<\/a>. We have more than\u202f400 open clinical trials<\/a>\u00a0and\u202f300 research teams<\/a>\u00a0studying cancer at any given time. More genes for inherited cancers have been discovered at Huntsman Cancer Institute than at any other cancer center. Our scientists are world-renowned for understanding how cancer begins and using that knowledge to develop innovative approaches to treat each patient\u2019s unique disease. Huntsman Cancer Institute was founded by Jon M. and Karen Huntsman.<\/p>\n","protected":false},"excerpt":{"rendered":"Newswise \u2014 A research team from\u00a0Huntsman Cancer Institute\u00a0at the\u00a0University of Utah (the U)\u00a0reports\u00a0that a groundbreaking\u00a0pathway-targeted therapy could be…\n","protected":false},"author":2,"featured_media":553545,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[8845,1698,103,396,23119,61,2747,60,234147,1378,2361],"class_list":["post-553544","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-clinical-trials","tag-dermatology","tag-health","tag-healthcare","tag-huntsman-cancer-institute-at-the-university-of-utah","tag-ie","tag-immunology","tag-ireland","tag-melanomaskin-cancer","tag-newswise","tag-public-health"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/553544","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/comments?post=553544"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/553544\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media\/553545"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media?parent=553544"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/categories?post=553544"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/tags?post=553544"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}